190 related articles for article (PubMed ID: 34974132)
1. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
2. Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.
Zhan L; Zhang J; Wei B; Cao Y
Autophagy; 2022 Apr; 18(4):942-943. PubMed ID: 35174769
[TBL] [Abstract][Full Text] [Related]
3. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
4. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
[TBL] [Abstract][Full Text] [Related]
5. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
6. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
7. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
8. LATS1/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression.
Yang Q; Lv Z; Wang M; Kong M; Zhong C; Gao K; Wan X
J Exp Clin Cancer Res; 2024 Feb; 43(1):54. PubMed ID: 38383447
[TBL] [Abstract][Full Text] [Related]
9. Coronavirus Porcine Deltacoronavirus Upregulates MHC Class I Expression through RIG-I/IRF1-Mediated NLRC5 Induction.
Liu X; Yin L; Xue M; Chen J; Li L; Fu F; Feng L; Liu P
J Virol; 2022 Apr; 96(7):e0015822. PubMed ID: 35311551
[TBL] [Abstract][Full Text] [Related]
10. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
11. NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.
Fan Y; Dong Z; Shi Y; Sun S; Wei B; Zhan L
J Int Med Res; 2020 May; 48(5):300060520925352. PubMed ID: 32431202
[TBL] [Abstract][Full Text] [Related]
12. NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.
Zhu SD; Zhang J; Liu XJ; Zhang JH; Wei B; Wang WY; Fan YJ; Li D; Cao YX; Zhan L
Technol Cancer Res Treat; 2022; 21():15330338221112742. PubMed ID: 35880269
[No Abstract] [Full Text] [Related]
13. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
14. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
15. Expression regulation and function of NLRC5.
Yao Y; Qian Y
Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
[TBL] [Abstract][Full Text] [Related]
16. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
17. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens.
Rodriguez GM; Yakubovich E; Murshed H; Maranda V; Galpin KJC; Cudmore A; Hanna AMR; Macdonald E; Ramesh S; Garson K; Vanderhyden BC
Front Immunol; 2023; 14():1295208. PubMed ID: 38235131
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
19. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
[TBL] [Abstract][Full Text] [Related]
20. NLRC5 deficiency has a moderate impact on immunodominant CD8
Sun T; Ferrero RL; Girardin SE; Gommerman JL; Philpott DJ
Immunol Cell Biol; 2019 Jul; 97(6):552-562. PubMed ID: 30768806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]